1. The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum

2. Program Outline

3. SGLT in the Intestine

4. SGLT in the Kidney

5. SGLT in the Kidney (cont)

6. Inhibition of SGLT

7. Inhibition of SGLT: Kidney

8. Inhibition of SGLT: Kidney and Intestine

9. Approval of SGLT Inhibitors

10. SGLT Inhibition in T2DM

11. Dapagliflozin Monotherapy 2-Year Study

12. Effect of SGLT-2 Inhibitors on HbA1c, SBP, and Bodyweight

13. CV Outcomes Trials With SGLT-2 Inhibitors in T2DM

14. Empagliflozin and Renal Parameters in EMPA-REG

15. CV Outcomes Trials: Renal Outcome Data

16. SGLT-2 Inhibition: Cardio-Renal Effects

17. SGLT Inhibition -- Expanding Opportunities

18. Unmet Need in T1DM

19. DEPICT-1 Trial: Dapagliflozin Adjunct to Insulin in T1DM

20. EASE Trials: Empagliflozin Adjunct to Insulin in T1DM

21. InTandem Trials: Sotagliflozin Adjunct to Insulin in T1DM

22. InTandem 3 Trial

23. Sotagliflozin: Reduction in Glucose Variability

24. Adverse Events With SGLT Inhibitors

25. Adverse Events: SGLT2 Inhibitors vs GLP-1 RAs

26. SGLT Inhibitors and DKA

27. SGLT Inhibitors and DKA (cont)

28. SGLT Inhibitors and DKA (cont)

29. International Consensus on DKA in T1DM With SGLT Inhibitors

30. International Consensus on DKA in T1DM With SGLT Inhibitors (cont)

31. Amputations: Clinical Trial and Real-World Data

32. Summary

33. Abbreviations

34. Abbreviations (cont)